New combo therapy for tough melanoma shows promise but trial halted early
NCT ID NCT04688658
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs—duvelisib (a pill) and nivolumab (an IV infusion)—in 13 people with advanced melanoma that had stopped responding to standard immunotherapy. The goal was to find a safe dose and see if the combination could shrink tumors or slow the disease. The trial was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat cancers
- Gene-Hacked immune cells take on tough cancers
- Engineered immune cells take on Hard-to-Treat melanoma
- Milder chemo before TIL therapy shows promise for tough-to-treat melanoma
- New combo tackles tough melanoma
- Second chance: Out-of-Spec cancer therapy offered to desperate patients